Corrigendum: The incidence risk of breast and gynecological cancer by antidepressant use: A systematic review and dose-response meta-analysis of epidemiological studies involving 160,727 patients

Front Oncol. 2022 Nov 8:12:1072594. doi: 10.3389/fonc.2022.1072594. eCollection 2022.

Yanjia Zhuang¹, Xiaogang Pang^{1

2}, Yuchen Qi³, Tianshu Zhang¹, Guimao Cao⁴, Heming Xue¹, Yifan Xu^{1

5}, Shuoxin Xie^{1

6}, Yifan Liu^{1

5}, Yinuo Wang^{1

5}, Yunxiao Li^{1

5}, Ying Xiong⁷, Yuanyuan Li¹, Hui Shen¹

¹ Laboratory of Brain Science, Innovation Research Institute of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
² Experimental Center, Shandong University of Traditional Chinese Medicine, Jinan, China.
³ School of health, Shandong University of Traditional Chinese Medicine, Jinan, China.
⁴ Department of Anesthesiology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China.
⁵ School of Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
⁶ School of Acupuncture, Shandong University of Traditional Chinese Medicine, Jinan, China.
⁷ Innovation Research Institute of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.

Abstract

[This corrects the article DOI: 10.3389/fonc.2022.939636.].

Keywords: Incidence; antidepressant; breast cancer; depression; dose-response analysis; gynecological cancer; meta-analysis; systematic review.